SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

Traders are focused on the Fed's interest rate decision and upcoming comments from Powell, with a rate cut largely priced in. Community chatter revolves around the potential market reaction, the end of quantitative tightening, and the possibility of a 'sell the news' event. Some are also watching for potential impacts from big tech earnings and upcoming meetings between Trump and Chinese leaders.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders react to Fed Chair Powell's comments and anticipate a potential rate cut decision, sparking volatility. Community members are debating whether recent market gains are sustainable amid concerns of an AI bubble and overvalued conditions. Discussions also include the potential impact of Trump's meeting with Xi on trade and tariffs.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

Despite a strong earnings report, UnitedHealth Group ($UNH) is trending due to a volatile price reaction, leading to mixed sentiment among traders. Some investors view the dip as a buying opportunity, while others express frustration over the stock's inability to sustain gains. Community discussions revolve around potential manipulation, analyst ratings, and speculation about Warren Buffett's position.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as traders debate its potential following mixed signals including upcoming Fed decisions and conflicting analysis from market commentators. Community members are actively discussing potential upcoming catalysts alongside concerns about market manipulation and recent price volatility. Broader conversations revolve around Ethereum's role in tokenization and its performance relative to traditional markets and other cryptocurrencies.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending as investors anticipate the release of HOPE-3 trial data in mid-November, with community members actively discussing potential positive outcomes and a possible short squeeze. Some traders are speculating about leaked data or insider information driving the recent price increase, while others highlight the potential of the StealthX exosome platform and the possibility of a large explosion upwards. The stock is also garnering attention due to its connection with Sarepta and BlackRock's significant stake in the company.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock drop following lowered guidance and leadership changes, sparking intense debate among investors. The community is discussing whether this presents a buying opportunity or signals deeper issues, with some citing an oversold condition while others point to concerning debt levels. Overall sentiment is mixed as traders assess the potential for a rebound versus further decline.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors react to mixed signals, including potential Fed rate cuts and ongoing trade tensions. The community is actively discussing whether recent price movements reflect a genuine flight to safety or a temporary reaction. Broader concerns around economic slowdown and the impact of tariffs on inflation are also contributing to the conversation.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing volatility as traders react to anticipated Federal Reserve decisions and related commentary, with community discussions focusing on potential impacts from rate cuts and QT tapering. Some traders believe a post-FOMC rally is likely, while others express concern about market manipulation and potential for further declines. Despite positive news like potential trade deals, Bitcoin's struggle to sustain upward momentum while stocks hit new highs fuels debates about its current cycle and future trajectory.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors anticipate its earnings report, focusing on Azure's growth and the impact of AI investments. Community discussions revolve around the potential for a breakout, with some speculating on a stock split and others monitoring the implications of Azure outages. The broader tech sector's performance and potential Federal Reserve actions add to the heightened interest in MSFT's upcoming results.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors anticipate upcoming earnings, with discussions focused on the potential impact of AI investments and advertising revenue growth. Community members are weighing in on forward guidance, especially capex spending, and some are speculating about a possible stock split. Despite broader market optimism, META's recent performance has sparked debate about its valuation and near-term direction.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel">announced</a> that the U.S. Food and Drug Administration (FDA) has approved its gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin disease with no known cure caused by a defect in the COL7A1 gene that leaves them unable to produce functioning type VII collagen.Patients with the disease have fragile skin characterized by extensive blistering and severe wounds that often cover more than 30% of the body surface. These wounds are difficult to heal, can remain open for years, and many that do close tend to reopen.Abeona stated that its ZEVASKYN sheet is the only FDA-approved product for treating RDEB wounds with a single application.ZEVASKYN consists of a patient’s skin cells that have been genetically modified to produce functional Type VII collagen. These sheets are then surgically applied to the patient’s wounded areas.Up to 12 credit card-sized sheets can be joined together to cover large areas in a single application, the company said.ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers (QTCs), which are treatment centers located across the U.S. with experience in cell and gene therapy.However, H.C. Wainwright stated on Tuesday that it does not expect ZEVASKYN to have an immediate impact on Krystal Biotech’s Vyjuvek. Vyjuvek is a topical gel aimed at wound healing in patients with dystrophic epidermolysis bullosa.Vyjuvek remains the "differentiated opportunity, particularly with regard to cost, surface area coverage for wound healing and quality of life/convenience," the analyst told investors in a research note, as per TheFly.<a href="https://stocktwits.com/symbol/ABEO">ABEO stock</a> is down by about 16% this year but up by over 44% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/paypal-flags-uncertainty-in-global-macro-environment/chQ6JJNRbLW">PayPal Reports Better-Than-Expected Q1 Earnings But Flags Uncertainty In Global Macro Environment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

Equity

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Abeona Therapeutics Inc. (Abeona or the Company...

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) on behalf of investors concerning the Companys possible violations of...

Abeona Therapeutics announces employee inducement grants

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

ABEO
Abeona Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ABEO News

ABEOAbeona Therapeutics Inc